114 related articles for article (PubMed ID: 4038309)
41. Assessment in mice of a synthetic peptide-based vaccine against the sporozoite stage of the human malaria parasite, P. falciparum.
Etlinger HM; Heimer EP; Trzeciak A; Felix AM; Gillessen D
Immunology; 1988 Jul; 64(3):551-8. PubMed ID: 3044983
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of adjuvanticity of promising new synthetic MDP analogues.
Alam A; Capoor AK; Rao LV
Immunol Lett; 1991 Jan; 27(1):53-7. PubMed ID: 2019420
[TBL] [Abstract][Full Text] [Related]
43. Monoclonal antibodies to the synthetic adjuvant muramyl dipeptide: characterization of the specificity.
Bahr GM; Eshhar Z; Ben-Yitzhak R; Modabber FZ; Arnon R; Sela M; Chedid L
Mol Immunol; 1983 Jul; 20(7):745-52. PubMed ID: 6888382
[TBL] [Abstract][Full Text] [Related]
44. Cross-reactivity between haptenic muramyl di- or tripeptide derivatives and Mycobacterium bovis BCG: potential application for enhancing tumor immunity.
Kosugi A; Shima J; Sano H; Ogata M; Kusama T; Fujiwara H; Hamaoka T
Infect Immun; 1986 Dec; 54(3):768-73. PubMed ID: 3491048
[TBL] [Abstract][Full Text] [Related]
45. Adjuvants of immunity.
Chedid L
Ann Inst Pasteur Immunol (1985); 1985; 136D(3):283-91. PubMed ID: 3913381
[No Abstract] [Full Text] [Related]
46. Adjuvant activity of some nonpyrogenic hydrophobic analogues of muramyl dipeptide in enhancing the primary humoral and cell mediated immune responses in guinea pig model.
Saxena RP; Puri A; Saxena KC; Shukla R; Haq W; Rizvi SY; Kundu B; Mathur KB
Indian J Exp Biol; 1991 Feb; 29(2):111-5. PubMed ID: 1869292
[TBL] [Abstract][Full Text] [Related]
47. "Universal" T helper cell determinants enhance immunogenicity of a Plasmodium falciparum merozoite surface antigen peptide.
Kumar A; Arora R; Kaur P; Chauhan VS; Sharma P
J Immunol; 1992 Mar; 148(5):1499-505. PubMed ID: 1371529
[TBL] [Abstract][Full Text] [Related]
48. [Vaccination against malaria: initial trial with an ant-sporozoite vaccine, (NANP)3-TT (RO 40-2361) in Africa (Bobo-Dioulasso, Burkina Faso)].
Guiguemdé TR; Sturchler D; Ouédraogo JB; Drabo M; Etlinger H; Douchet C; Gbary AR; Haller L; Kambou S; Fernex M
Bull Soc Pathol Exot; 1990; 83(2):217-27. PubMed ID: 2119897
[TBL] [Abstract][Full Text] [Related]
49. Further study on relationship of anti-tuberculous protection to lung granulomata produced by intravenous injections of synthetic 6-0-mycoloyl-N-acetyl-muramyl-L-alanyl-D-isoglutamine with or without specific antigens.
Yamamoto K; Kato K; Kakinuma M; Okuyama H; Azuma I
Immunology; 1982 Jun; 46(2):473-9. PubMed ID: 7044961
[TBL] [Abstract][Full Text] [Related]
50. Liposomes, muramyl dipeptide derivatives, and nontoxic lipid A derivatives as adjuvants for human malaria vaccines.
Hui GS
Am J Trop Med Hyg; 1994; 50(4 Suppl):41-51. PubMed ID: 8172331
[TBL] [Abstract][Full Text] [Related]
51. A synthetic vaccine against influenza with built-in adjuvanticity.
Shapira M; Jolivet M; Arnon R
Int J Immunopharmacol; 1985; 7(5):719-23. PubMed ID: 4044097
[TBL] [Abstract][Full Text] [Related]
52. Induction of antibodies directed against self and altered-self determinants by a synthetic adjuvant, muramyl dipeptide and some of its derivatives.
Löwy I; Leclerc C; Chedid L
Immunology; 1980 Mar; 39(3):441-50. PubMed ID: 6160092
[TBL] [Abstract][Full Text] [Related]
53. Model using a peptide with carrier function for vaccination against different pathogens.
Etlinger HM; Knorr R
Vaccine; 1991 Jul; 9(7):512-4. PubMed ID: 1716809
[TBL] [Abstract][Full Text] [Related]
54. Enhancement of serum antibody production in mice by oral administration of lipophilic derivatives of muramyl peptides and bacterial lipopolysaccharides with bovine serum albumin.
Ogawa T; Kotani S; Shimauchi H
Methods Find Exp Clin Pharmacol; 1986 Feb; 8(2):117-25. PubMed ID: 3713372
[TBL] [Abstract][Full Text] [Related]
55. Enhancement of serum antibody production in mice by oral administration of lipophilic derivatives of muramylpeptides and bacterial lipopolysaccharides with bovine serum albumin.
Ogawa T; Kotani S; Shimauchi H
Methods Find Exp Clin Pharmacol; 1986 Jan; 8(1):19-26. PubMed ID: 3702542
[TBL] [Abstract][Full Text] [Related]
56. Cyclic OmpC peptidic epitope conjugated to tetanus toxoid as a potential vaccine candidate against shigellosis.
Jarząb A; Witkowska D; Ziomek E; Setner B; Czajkowska A; Dorot M; Szewczuk Z; Gamian A
Vaccine; 2018 Jul; 36(31):4641-4649. PubMed ID: 29960802
[TBL] [Abstract][Full Text] [Related]
57. Assays for adjuvanticity of new formulations and of carrier proteins for inducing antibody responses to selected immunogens in the squirrel monkey Saimiri sciureus.
Perraut R; Chouteau P; Bourreau E; Bonnemains B; Garraud O
Immunol Cell Biol; 1994 Apr; 72(2):169-75. PubMed ID: 8200692
[TBL] [Abstract][Full Text] [Related]
58. New developments in the field of synthetic muramyl peptides, especially as adjuvants for synthetic vaccines.
Lederer E
Drugs Exp Clin Res; 1986; 12(6-7):429-40. PubMed ID: 3527628
[TBL] [Abstract][Full Text] [Related]
59. Murine IgG isotype responses to the Plasmodium cynomolgi circumsporozoite peptide (NAGG)5. I. Effects of carrier, copolymer adjuvants, and lipopolysaccharide on isotype selection.
Kalish ML; Check IJ; Hunter RL
J Immunol; 1991 May; 146(10):3583-90. PubMed ID: 2026882
[TBL] [Abstract][Full Text] [Related]
60. New muramyl dipeptide (MDP) mimics without the carbohydrate moiety as potential adjuvant candidates for a therapeutic hepatitis B vaccine (HBV).
Zhao N; Ma Y; Zhang S; Fang X; Liang Z; Liu G
Bioorg Med Chem Lett; 2011 Jul; 21(14):4292-5. PubMed ID: 21683593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
